IMUX
Immunic IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$177.76M
P/E Ratio
—
EPS
$-4.77
Beta
1.21
52W High
$15.10
52W Low
$5.06
50-Day MA
$11.27
200-Day MA
$8.78
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunic Inc
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-109.48M |
| Operating Margin | 0.00% |
| Return on Equity | -142.90% |
| Return on Assets | -65.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.55 |
| Price-to-Book | 1.18 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.62M |
| Float | $10.49M |
| % Insiders | 0.97% |
| % Institutions | 48.26% |
Historical Volatility
HV 10-Day
71.63%
HV 20-Day
87.22%
HV 30-Day
88.41%
HV 60-Day
98.41%
HV Rank
57.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($44.67 target)
8
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026